Amazon Biotech Announces Appointment of Chaim J. Lieberman, the Inventor and Founder, as New Successor for Management

Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that Mr. Chaim J. Lieberman, the inventor and founder of Amazon Biotech Inc., was appointed as sole successor for management to Mr. Eliyahu Bental/Tolchinsky and Mr. Bental resigned.

Mr. Lieberman is quoted as saying,"I look forward to investing good energy to focus the company on its pharmaceutical vision and goals."

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immune modulator drugs. AMZ0026 is the Company's first such drug approved for Phase 2 HIV/Aids human trials by the FDA. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/ .

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.

For more information contact www.amazonbiotech.com cj@amazonbiotech.com IR Contact: LC Group Rick Lutz 404-261-1196 lcgroup@mindspring.com